FINWIRES · TerminalLIVE
FINWIRES

Centuria Capital Group's World Square Purchase 'At Odds' With Current Market Preference, Jefferies Says

By

Centuria Capital Group's (ASX:CNI) World Square purchase appears to be "at odds" with the market's preference for prime-grade assets, and also marks a doubling-down on secondary office space at a time when the company's listed satellite is trading close to an all-time low, Jefferies said in a May 11 note.

The company's purchase of a 21-year-old office asset in a sub-optimal part of the central business district that is roughly 88% occupied represents Centuria Capital assuming a large counter-cyclical view on the Sydney office market, the equity research firm said.

"Convincing listed equity investors of the upside potential, and that it is the right move at this point in the office & rate cycles has been been met with a level of skepticism," Jefferies said.

It added that despite this, the acquisition and associated capital raising would result in an estimated 4% accretion to its fiscal 2027 operating earnings per security forecast for the company.

Centuria Capital likely has its work cut out to lease up the 12% of existing vacancy "in a very challenged mid-town market," but the vendor has issued a two-year rental guarantee over this income, which will help underwrite the targeted 7.5% annual distribution yield in the near term, Jefferies said.

Jefferies maintained a buy rating on the company with a price target of AU$2.50.

Centuria Capital Group's shares were down 1% in recent Tuesday trade.

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

HKG:1093HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

ASX:ATH